Ottawa, Ontario (PRWEB) March 05, 2014
Spartan Bioscience today announced the start of a study of personalized medicine at the University of Florida. The Spartan RX CYP2C19 System is being used to test heart attack patients receiving cardiac stents. The study is entitled “A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function Genotypes” and is scheduled to finish in April 2015.
The principal investigator is Dominick Angiolillo, M.D., Ph.D., the Director of Cardiovascular Research and Associate Professor of Medicine at the University of Florida College of Medicine. Dr. Angiolillo has authored over 250 peer-reviewed articles, including seminal studies on the genetics of antiplatelet drug response.
“Thanks to Spartan, we can now get rapid genetic results at the time of cardiac stenting,” said Dr. Angiolillo. “This makes it practical to provide personalized antiplatelet therapy.”
The CYP2C19 enzyme metabolizes approximately 15 percent of all prescribed drugs(1), including important drug classes such as antiplatelet therapies, beta blockers, antidepressants, proton pump inhibitors, and anti-epileptics. About 30% of Caucasians, and more than 50% of Asians and Indians carry CYP2C19 gene variants that reduce response to drugs metabolized by CYP2C19.(2,3,4,5)
About Spartan Bioscience
Spartan Bioscience is the leader in on-demand DNA testing.(6) Spartan is bringing complete sample-to-result DNA testing systems to medicine. Spartan’s technology fully integrates DNA collection, extraction, and analysis, with an intuitive interface that is easy to operate. For the first time, healthcare providers and their patients can get DNA results on demand. For more information, please visit our website at: http://www.spartanbio.com.
The Spartan logo is a registered trademark of Spartan Bioscience Inc.
1. dbSNP Short Genetic Variations. Reference SNP (refSNP) Cluster Report: rs12248560
2. Damani SB, Topol EJ. (2010). J Am Coll Cardiol. 56:109–11.
3. Chen M et al. (2011). Atherosclerosis. 220(1):168–71.
4. Oh IY et al. (2012). Heart. 98(2):139–44.
5. Jose R et al. (2004). Fundamental & Clinical Pharmacology. 19(1): 101–105.
6. Roberts JD et al. (2012). Lancet. 379:1705–11.